Clinical trials: Hydroxychloroquine
COVID-19
PROLIFIC ChemoprophylaxisTrial (COVID-19)
The number of confirmed cases of COVID-19 infectious disease arising from the SARS-CoV-2 coronavirus is rising substantially and rapidly, with the potential to overwhelm the ability of the entire National Health Service (NHS) to…
- Trial name
- NCT04352933
- Testing
- Hydroxychloroquine - Daily dosing, Hydroxychloroquine - Weekly Dosing
- Where
- United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Estrogen Receptor Positive Breast Cancer
Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy
To determine the safety and tolerability of orally administered hydroxychloroquine with hormonal therapy. To assess the response rate of hydroxychloroquine in combination with hormonal therapy.
- Trial name
- ABC01 (NCT02414776)
- Testing
- hydroxychloroquine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Western Regional Medical Center
Colorectal Cancer
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
This will be a randomized phase II clinical trial of patients with histologic documentation of metastatic colorectal cancer, who have received local and currently approved standard therapies, excluding RGF.
- Trial name
- NCT02316340
- Testing
- Vorinostat, Hydroxychloroquine, Regorafenib
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
COVID-19, SARS-CoV-2
Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)
This is a prospective, randomized, double-blinded, placebo-controlled, pilot study to assess the preliminary efficacy and safety of hydroxychloroquine for the treatment of patients with lower respiratory tract SARS-CoV-2…
- Trial name
- NCT04363866
- Testing
- Hydroxychloroquine
- Where
- United States
- Sponsor
- Oregon Health and Science University
Antiphospholipid Syndrome (APS)
Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome
This study evaluates the benefits of hydroxychloroquine on arterial function in antiphospholipid syndrome. Briefly, the patients will be randomized in two groups, one will receive hydroxychloroquine and standard treatment, the…
- Trial name
- APLAQUINE (NCT02595346)
- Testing
- Hydroxychloroquine
- Where
- France
- Volunteers
- 25 people
- Sponsor
- University Hospital, Rouen
Covid19, Progression
Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression
Brief Summary: Purpose of this study is to evaluate efficacy of hydroxychloroquine (HCQ) in reducing progression of Corona Virus Disease 2019 (COVID - 19) and achieving viral clearance.
- Trial name
- COVID-19 (NCT04491994)
- Testing
- HCQ
- Where
- Pakistan
- Volunteers
- 540 people
- Sponsor
- UNICEF
Congenital Heart Block, Neonatal Lupus
Preventive Approach to Congenital Heart Block With Hydroxychloroquine
Women with antibodies to proteins called SSA/Ro and or SSB/La face a 2% chance of having a child with a life threatening heart condition regardless of whether they have very active lupus, are in remission, or have only vague…
- Conditions
- Congenital Heart Block, Neonatal Lupus, Autoantibody-Associated Heart Block
- Trial name
- PATCH (NCT01379573)
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- NYU Langone Health
COVID-19, Corona Virus Infection
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care
This study will assess the efficacy of hydroxychloroquine in reducing the severity of symptoms in patients with COVID-19
- Conditions
- COVID-19, Corona Virus Infection, SARS-CoV-2, 2019-nCoV
- Trial name
- NCT04334967
- Testing
- Hydroxychloroquine, Vitamin C
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Providence Health & Services
Recurrent Miscarriage, First Trimester Abortion
Hydroxychloroquine for Prevention of Recurrent Miscarriage.
Recurrent miscarriage (RM) defined by >=3 consecutive losses affects 1% of fertile couples. Most women have recurrent early loss with a failure of development before 10 weeks' gestation.
- Trial name
- BBQ (NCT03165136)
- Testing
- Hydroxychloroquine
- Where
- 18 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Brest
Rheumatoid Arthritis
Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis
Rheumatoid arthritis (RA) increase cardiovascular risk and endothelial dysfunction. Hydroxychloroquine (HCQ) is expected to improve endothelial dysfunction through some metabolic effects.
- Trial name
- NCT03085940
- Testing
- Hydroxychloroquine
- Where
- Indonesia
- Volunteers
- 37 people
- Sponsor
- Universitas Indonesia
Systemic Lupus, Skin Lupus
Lupus and Observance
A poor therapeutic observance is described between 3 and 76% cases in systemic lupus. It is associated with an increased risk of relapses, hospitalizations, morbidity and poor renal prognosis.
- Trial name
- LUPOBS (NCT03019926)
- Testing
- Hydroxychloroquine dosage
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital Center of Martinique
Prostate Cancer
Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
The purpose of this study is to assess the effect of combining abiraterone with medicines that may block some of the ways that cells become resistant to abiraterone.
- Trial name
- NCT01828476
- Testing
- Abiraterone, ABT-263, Hydroxychloroquine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Rutgers, The State University of New Jersey
Malignant Solid Tumour
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
This study is an open label non randomized study of hydroxychloroquine (HCQ) with histone deacetylase (HDAC) inhibitor Vorinostat in patients with advanced solid tumors to determine the maximum tolerated dose (MTD) and to…
- Trial name
- NCT01023737
- Testing
- Hydroxychloroquine, Vorinostat
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Acute Myeloid Leukemia
Hydrochloroquinine & Decitabine With Venetoclax in AML
Phase I: Primary Objective: Determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of the o-Dec, ven, and HCQ Secondary Objectives: Characterize the safety profile of the triplet Estimate the efficacy of…
- Trial name
- NCT07814339
- Testing
- Hydroxychloroquine, Venetoclax, Oral Decitabine/cedazuridine
- Volunteers
- 18 people
- Sponsor
- Rutgers, The State University of New Jersey
SARS-CoV Infection
Chemoprevention Clinical Trial of COVID-19: Hydroxychloroquine Post Exposure Prophylaxis
Protocol summary Title A Prospective, randomized, adaptive phase II/III clinical trial, controlled, open-label, chemoprevention, 3-arms, parallel, multi-centred, to A Prospective, randomized, clinical trial, controlled…
- Trial name
- APCC-19 (NCT04597775)
- Testing
- hydroxychloroquine
- Volunteers
- 93 people
- Sponsor
- Regional Center for Disease Control and Prevention, Jordan
Primary Sjögren's Syndrome
Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome
Primary Sjögren's syndrome (SJp) affects 0.1% of the population. This systemic autoimmune disease systemic is characterized by disabling dryness, fatigue and pain, and systemic complications in 30% of patients.
- Trial name
- JOQUER (NCT00632866)
- Testing
- Hydroxychloroquine
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Retinitis Pigmentosa
Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)
This research study is being done to learn what effect 12 months of treatment with oral hydroxychloroquine (HCQ) will have on the retina in people with retinitis pigmentosa (RP).
- Trial name
- NCT04120883
- Testing
- Hydroxychloroquine lower dose, Hydroxychloroquine higher dose
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Michigan
Multiple Myeloma and Plasma Cell Neoplasm
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00568880
- Testing
- bortezomib, hydroxychloroquine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
COVID-19
High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19
This study aims to examine the tolerability of high dose hydroxychloroquine in patients with COVID-19 who are not yet hospitalized, but have risk factors for disease progression and complications.
- Trial name
- NCT04351620
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
Advanced BRAF Mutant Melanoma
Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
The primary purpose of this study is to determine the maximum tolerated dose (MTD) and preliminary safety of hydroxychloroquine (HCQ) when administered in conjunction with oral dabrafenib and trametinib (D+T) in patients with…
- Trial name
- BAMM (NCT02257424)
- Testing
- Trametinib 2 mg daily, hydroxychloroquine (HCQ), dabrafenib 150 mg orally twice a day
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Abramson Cancer Center at Penn Medicine